The Journal of Allergy and Clinical Immunology
Volume 114, Issue 6 , Pages 1449-1455 , December 2004

Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700

  • Yae-Jean Kim, MD

      Affiliations

    • From the Laboratory of Parasitic Diseases
    • ,
  • Calman Prussin, MD

      Affiliations

    • Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda; Md
    • ,
  • Brian Martin, BS

      Affiliations

    • From the Laboratory of Parasitic Diseases
    • ,
  • Melissa A. Law, RN

      Affiliations

    • From the Laboratory of Parasitic Diseases
    • ,
  • Thomas P. Haverty, MD

      Affiliations

    • Schering-Plough Research Institute, Kenilworth, NJ
    • ,
  • Thomas B. Nutman, MD

      Affiliations

    • From the Laboratory of Parasitic Diseases
    • ,
  • Amy D. Klion, MD

      Affiliations

    • From the Laboratory of Parasitic Diseases
    • Corresponding Author InformationReprint requests: Amy D. Klion, MD, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bldg 4, Rm B1-05, 9000 Rockville Pike, Bethesda, MD 20892.

Received 2 March 2004 ,Revised 8 August 2004 ,Accepted 10 August 2004.

References 

  1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1–27
  2. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon α. J Allergy Clin Immunol. 1994;94:1318–1326
  3. Parrillo JE, Fauci AS, Wolff SM. The hypereosinophilic syndrome: dramatic response to therapeutic intervention. Trans Assoc Am Physicians. 1977;90:135–144
  4. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660–4666
  5. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391–3397
  6. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881–884
  7. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714–4716
  8. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214
  9. Lee M, Hodges WG, Huggins TL, Lee EL. Eosinophilic gastroenteritis. South Med J. 1996;89:189–194
  10. Kelly KJ. Eosinophilic gastroenteritis. J Pediatr Gastroenterol Nutr. 2000;30:S28–S35
  11. Egan RW, Athwal D, Bodmer MW, Carter JM, Chapman RW, Chou C, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49:779–790
  12. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167:1655–1659
  13. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103:2939–2941
  14. Prussin C, James SP, Huber MM, Klion AD, Metcalfe DD. Pilot study of anti-IL-5 in eosinophilic gastroenteritis. J Allergy Clin Immunol. 2003;111:S275
  15. Hansel TT, De Vries IJ, Iff T, Rihs S, Wandzilak M, Betz S, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods. 1991;145:105–110
  16. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334–2339
  17. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, et al. Decreased expression of membrane IL-5 receptor α on human eosinophils, II: IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol. 2002;169:6459–6466
  18. Hellman C, Hallden G, Hylander B, Lundahl J. Regulation of the interleukin-5 receptor α-subunit on peripheral blood eosinophils from healthy subjects. Clin Exp Immunol. 2003;131:75–81
  19. Zabeau L, Van der Heyden J, Broekaert D, Verhee A, Vandekerckhove J, Wu SJ, et al. Neutralizing monoclonal antibodies can potentiate IL-5 signaling. Eur J Immunol. 2001;31:1087–1097
  20. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects: the mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol. 1993;151:3853–3865
  21. Enokihara H, Furusawa S, Nakakubo H, Kajitani H, Nagashima S, Saito K, et al. T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood. 1989;73:1809–1813
  22. Walker C, Virchow JC, Bruijnzeel PL, Blaser K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol. 1991;146:1829–1835
  23. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111:714–719
  24. Finkelman FD, Morris SC. Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol. 1999;11:1811–1818

PII: S0091-6749(04)02241-9

doi: 10.1016/j.jaci.2004.08.027

The Journal of Allergy and Clinical Immunology
Volume 114, Issue 6 , Pages 1449-1455 , December 2004

Article Tools

* Image Usage & Resolution